Ortho Clinical Diagnostics
100 Indigo Creek Drive
Rochester
New York
14626
United States
Tel: 800-828-6316
Fax: 585-453-3660
Website: http://www.orthoclinical.com/
121 articles about Ortho Clinical Diagnostics
-
REPLACING: Ortho Clinical Diagnostics Reports Fourth Quarter and Fiscal Year 2020 ResultsFourth Quarter Revenue Growth Ahead of Company Expectations at 9.1%
3/19/2021
In a release issued earlier today under the same headline by Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), please note that in the last sentence of the first paragraph under the “Fourth Quarter 2020 Operational Highlights” section, the COVID-19 test is an antigen test, not an antibody test.
-
Ortho Clinical Diagnostics Reports Fourth Quarter and Fiscal Year 2020 ResultsFourth Quarter Revenue Growth Ahead of Company Expectations at 9.1%
3/18/2021
Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world's largest pure-play in-vitro diagnostics (IVD) companies, today announced financial results for the fourth quarter and fiscal year ended January 3, 2021. Highlights
-
Ortho Clinical Diagnostics Names Evelyn Dilsaver to Board of DirectorsFormer CEO of Charles Schwab Investment Management will also serve as audit committee chair
2/23/2021
Ortho Clinical Diagnostics, one of the world’s largest pure-play in vitro diagnostics companies dedicated to transforming patient care, announced that Evelyn Dilsaver, former CEO of Charles Schwab Investment Management, has been appointed as a member of its board of directors and will serve as audit committee chair.
-
Ortho Clinical Diagnostics Announces Rating Upgrades by S&P Global and Moody’sAgencies Provide Stable Outlook Following Company’s Initial Public Offering
2/17/2021
Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) ("Ortho"), one of the world's largest pure-play in vitro diagnostics companies, today announced that S&P Global upgraded Ortho’s issuer credit rating to “B” from “B-” and Moody’s investment Services (“Moody’s”) upgraded Ortho’s Corporate Family Rating to “B1” from “B3.”
-
Ortho Clinical Diagnostics Amends Credit Agreement to Extend Maturity and Increase Borrowing Capacity Under its Revolving Credit Facility
2/9/2021
Ortho Clinical Diagnostics Holdings plc, one of the world's largest pure-play in vitro diagnostics companies, announced that certain of its subsidiaries successfully amended their June 30, 2014 credit agreement on February 5, 2021.
-
Ortho Clinical Diagnostics Announces Closing of Full Over-Allotment Option from Initial Public Offering
2/4/2021
Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) ("Ortho"), the world's largest pure-play in vitro diagnostics company dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions, today announced the closing of its sale of an additional 11.4 million ordinary shares
-
Ortho's VITROS® SARS-CoV-2 Antigen Test for Accurate, Mass-Scale COVID-19 Testing is the First High-Volume Test to Receive FDA Emergency Use Authorization
1/12/2021
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced that its VITROS® SARS-CoV-2 Antigen Test, designed to detect active infection, has become the first high-volume COVID-19 antigen test to receive U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA).
-
ORTHO Optix™ Reader Now Available in CE Mark Countries, Completes Transfusion Medicine Portfolio
11/30/2020
Ortho Clinical Diagnostics announced the CE Mark availability of the semi-automated ORTHO Optix™ Reader, which allows lower-volume transfusion labs to elevate their standard of patient care with the quality of results expected of an automated platform.
-
U.S. FDA Accepts Ortho's Emergency Use Notification for VITROS® SARS-CoV-2 Antigen Test--Capable of Accurate Mass-Scale Testing
11/4/2020
- Offered with 100 percent sensitivity[i] with samples with a PCR Cycle Threshold (CT) of less than 34, Ortho's test may be better able to identify individuals with COVID-19 who are infectious compared to PCR - Ortho's new SARS-CoV-2 antigen test is the latest addition to the company's COVID-19 solutions, which include two COVID-19 antibody tests, Total and IgG--both of which have CE Mark and FDA Emergency Use Authorization
-
Ortho's VITROS® SARS-CoV-2 Antigen Test Capable of Accurate Mass-Scale Testing Achieves CE Mark
10/26/2020
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced that its new VITROS® SARS-CoV-2 Antigen test, designed to detect active SARS-CoV-2 infection, achieved CE Mark for distribution throughout the EU.
-
Ortho Clinical Diagnostics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
10/16/2020
Ortho Clinical Diagnostics ("Ortho"), today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") relating to its proposed initial public offering. The number of shares to be offered and the price range for the proposed offering have not yet
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 23, 2020.
-
Ortho Awarded BARDA Contract to Accelerate Antigen Test Development and Additional SARS-CoV-2 Antibody Test Milestones
9/21/2020
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced its continued collaboration with the Biomedical Advanced Research and Development Authority ( BARDA ), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, in a new contr
-
Quotient Limited and Ortho Clinical Diagnostics Settle Arbitration and Sign Binding Letter of Intent Covering Patient Transfusion Diagnostics
9/8/2020
Quotient Limited, headquartered in Eysins, Switzerland, announced that the Company and Ortho Clinical Diagnostics have signed a binding letter of intent that confirms the termination of their former distribution agreement and related contracts and resolves all their disputes over the former distribution agreement.
-
Ortho Announces Board of Director Appointments
9/1/2020
Noted Diagnostic Industry Veteran David B. Perez Joins as an Independent Director Chris Smith Appointed Chairman of the Board, in addition to current CEO role
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 26, 2020.
-
Ortho Care™ Again Ranks No. 1 for Service in Diagnostics Industry
7/21/2020
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics with a worldwide reputation for top-rated customer service and support, today announced that its Ortho Care™ holistic service and support program was ranked No. 1 in the diagnostics industry for a fifth straight year.
-
Ortho Clinical Diagnostics Names Joseph M. Busky Chief Financial Officer
7/6/2020
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics backed by The Carlyle Group, announced Joseph M. Busky has joined the Company as Chief Financial Officer, effective July 7, 2020.
-
BARDA and Ortho Collaborate to Advance Development of High Specificity SARS-CoV-2 Antibody Tests
6/17/2020
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced it is collaborating with Biomedical Advanced Research and Development Authority ( BARDA ), a component of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to further advance the de
-
Ortho's COVID-19 IgG Antibody Test Receives CE Mark
5/18/2020
Ortho's IgG test demonstrates 100% specificity and can be used to support decisions for getting people back to work and can support convalescent plasma screening